Sandbox: malabsorption: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:
!
!
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
| colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" |Clinical manifestation
| colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" |'''Clinical manifestation'''
! colspan="4" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Lab findings
! colspan="4" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Lab findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Additional findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Additional findings
Line 13: Line 13:
|-
|-
!
!
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" ||Symptoms
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" |Symptoms
!align="center" style="background:#4479BA; color: #FFFFFF;" |Signs
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Signs
|-
|-
!
!
Line 27: Line 27:
! align="center" style="background:#4479BA; color: #FFFFFF;" |Bloody
! align="center" style="background:#4479BA; color: #FFFFFF;" |Bloody
! align="center" style="background:#4479BA; color: #FFFFFF;" |Fatty
! align="center" style="background:#4479BA; color: #FFFFFF;" |Fatty
!
! align="center" style="background:#4479BA; color: #FFFFFF;" |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hgb
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hgb
Line 36: Line 35:
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
Line 69: Line 68:
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 103: Line 102:
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 130: Line 129:
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 157: Line 156:
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 192: Line 191:
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
Line 219: Line 218:
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 253: Line 252:
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 276: Line 275:
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 302: Line 301:
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 325: Line 324:
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 353: Line 352:
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 385: Line 384:
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
Line 416: Line 415:
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 444: Line 443:
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 465: Line 464:
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 483: Line 482:
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 500: Line 499:
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 517: Line 516:
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 534: Line 533:
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 551: Line 550:
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 568: Line 567:
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 585: Line 584:
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 602: Line 601:
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 619: Line 618:
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 636: Line 635:
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 652: Line 651:
! align="center" style="background:#DCDCDC;" |[[Giardiasis]]
! align="center" style="background:#DCDCDC;" |[[Giardiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 668: Line 667:
! align="center" style="background:#DCDCDC;" |[[Strongyloidiasis]]
! align="center" style="background:#DCDCDC;" |[[Strongyloidiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 684: Line 683:
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  

Revision as of 16:19, 29 November 2017

Abbreviations: WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A

Cause Clinical manifestation Lab findings Additional findings Cause/Pathogenesis Gold standard diagnosis
Symptoms Signs
Diarrhea Fever Abdominal pain Weight loss
Watery Bloody Fatty WBC Hgb Plt Other lab findings
Whipple's disease + - + ± + + ↓/↑
Celiac disease ± - ± - + + - -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Tropical sprue + - + + + + - -
  • Diagnosis of exclusion
Crohns disease + + + + + +
  • Abnormal immune response to self antigens
Ulcerative colitis + + + + + +
  • Hypoalbuminemia
  • Hypokalemia
  • Hypomagnesemia
  • Iron deficiency
  • Elevated ESR
  • Elevated CRP
  • Abnormal immune response to self antigens
Cystic fibrosis - - + ± + + - -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
VIPoma + - + - + + - - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome + - + - + + - -
  • Elevated basal or stimulated serum gastrin> 120 pg/mL
Eosinophilic gastroenteritis  + - + - + + - -
Primary bile acid malabsorption + - + - + + - -
Abetalipoproteinemia + - + - + + - - -
Microscopic colitis + + - - + + - -
Hyperthyroidism + - - ± + + - - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Lactose intolerance + - - - + - - - -
Irritable bowel syndrome ± - ± - ± - - - -
  • Diagnosis of exclusion
Chronic pancreatitis + - + - + +
Cirrhosis + - + + + +
Short bowel syndrome -
Intestinal lymphoma
Agammaglobulinemia
Intestinal lymphangiectasia
Amyloidosis
Mastocytosis
Small intestinal bacterial overgrowth
Drug induced enteritis
Infection HIV infection
Giardiasis
Strongyloidiasis
Tuberculosis